Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.78
- Piotroski Score 7.00
- Grade Outperform
- Symbol (RVTY)
- Company Revvity, Inc.
- Price $111.08
- Changes Percentage (-0.23%)
- Change -$0.26
- Day Low $109.72
- Day High $114.13
- Year High $129.50
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
- Last Earnings 10/24/2024
- Ex-Dividend for 5/16 Dividend 01/17/2025
- Dividend Payable 02/07/2025
- Today N/A
- Next Earnings (Estimated) 01/29/2025
- Fiscal Year End N/A
- Average Stock Price Target $126.50
- High Stock Price Target $140.00
- Low Stock Price Target $110.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.47
- Trailing P/E Ratio 75.46
- Forward P/E Ratio 75.46
- P/E Growth 75.46
- Net Income $693.09 M
Income Statement
Quarterly
Annual
Latest News of RVTY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Revvity Inc (RVTY) Q3 2024 Earnings Call Highlights: Strong EPS and Cash Flow Amid Market Challenges
CEO Prahlad Singh discusses expectations for 2025 organic growth, recovery trends, and China instrument sales. Share repurchases will continue supported by strong finances. Reproductive health trends ...
By Yahoo! Finance | 2 weeks ago -
Some Investors May Be Willing To Look Past Revvity's (NYSE:RVTY) Soft Earnings
Despite soft profit numbers, the market reacted positively to Revvity, Inc.'s recent earnings report. The $145m unusual expense impacted profits, but analysts believe the underlying earnings potential...
By Yahoo! Finance | 3 months ago -
Is Revvity, Inc.'s (NYSE:RVTY) Recent Price Movement Underpinned By Its Weak Fundamentals?
Revvity's stock declined 6.6% recently, prompting an analysis of its financials. The company's low ROE of 2.3% is concerning compared to the industry average of 12%....
By Yahoo! Finance | 4 months ago
